FASN and pulmonary arterial hypertension: Reduction of de novo fatty acid production by blocking fatty acid synthase (FAS) using siRNA or C75, a FAS inhibitor, reverses PAH progression in the RV of animal models, demonstrating that fatty acid synthesis constitutes a potential therapeutic target in PAH (Singh et al., 2016).